Martinsried/Munich, 7 January 2016. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at three upcoming conferences:
- J.P. Morgan 34th Annual Healthcare Conference
Date: 11 - 14 January 2016
Location: San Francisco, CA, USA
- Phacilitate Cell & Gene Therapy World
Date: 25 - 26 January 2016
Location: Washington DC, USA
Prof. J. Dolores Schendel, CSO and designated CEO of Medigene will speak on 26 January, 2.45 - 3.05 pm on the following topic: "Tailoring immunotherapies of cancer for stage and type of disease"
- The 2nd Biologics and Biosimilars Congress
Date: 1 - 2 February 2016
Location: Berlin, Germany
Medigene will present on 2 February, 2.35 - 3 pm on the following topic: "TCR gene therapy: Developing technologies for now and the future: Essentials needed for a TCR tool box"
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and EndoTAG® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01, Email: firstname.lastname@example.org
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (email@example.com). We will then delete your address from our distribution list.